53 related articles for article (PubMed ID: 33351221)
1. Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy.
R Buskbjerg C; Zachariae R; Buus S; H Gravholt C; Haldbo-Classen L; Hosseini SMH; Amidi A
Cancer; 2021 May; 127(9):1495-1506. PubMed ID: 33351221
[TBL] [Abstract][Full Text] [Related]
2. Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.
Gonzalez BD; Jim HS; Booth-Jones M; Small BJ; Sutton SK; Lin HY; Park JY; Spiess PE; Fishman MN; Jacobsen PB
J Clin Oncol; 2015 Jun; 33(18):2021-7. PubMed ID: 25964245
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment: A Population-based Study.
Alonso Quiñones HJ; Stish BJ; Hagen C; Petersen RC; Mielke MM
Alzheimer Dis Assoc Disord; 2020; 34(2):118-121. PubMed ID: 31821185
[TBL] [Abstract][Full Text] [Related]
4. Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients.
Ng DQ; Cheng I; Wang C; Tan CJ; Toh YL; Koh YQ; Ke Y; Foo KM; Chan RJ; Ho HK; Chew L; Bin Harunal Rashid MF; Chan A
Sci Rep; 2023 Sep; 13(1):16298. PubMed ID: 37770565
[TBL] [Abstract][Full Text] [Related]
5. Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.
Verma S; Singh V; Nagampalli V; Ponsky LE; Li CR; Chao H; Gupta S
Mol Carcinog; 2024 Jun; 63(6):1051-1063. PubMed ID: 38482990
[TBL] [Abstract][Full Text] [Related]
6. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?
Mandelblatt JS; Stern RA; Luta G; McGuckin M; Clapp JD; Hurria A; Jacobsen PB; Faul LA; Isaacs C; Denduluri N; Gavett B; Traina TA; Johnson P; Silliman RA; Turner RS; Howard D; Van Meter JW; Saykin A; Ahles T
J Clin Oncol; 2014 Jun; 32(18):1909-18. PubMed ID: 24841981
[TBL] [Abstract][Full Text] [Related]
7. Serum brain-derived neurotrophic factor levels in type 2 diabetes mellitus patients and its association with cognitive impairment: A meta-analysis.
He WL; Chang FX; Wang T; Sun BX; Chen RR; Zhao LP
PLoS One; 2024; 19(4):e0297785. PubMed ID: 38648255
[TBL] [Abstract][Full Text] [Related]
8. Cancer-related cognitive impairment and wellbeing in patients with newly diagnosed aggressive lymphoma compared to population norms and healthy controls: an exploratory study.
Gates P; Dhillon HM; Krishnasamy M; Wilson C; Gough K
Support Care Cancer; 2024 Mar; 32(4):238. PubMed ID: 38512692
[TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.
Wu LM; Amidi A
Curr Opin Support Palliat Care; 2017 Mar; 11(1):38-45. PubMed ID: 27926544
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and biologic characteristics of cancer-related cognitive impairment biotypes.
Mulholland MM; Prinsloo S; Kvale E; Dula AN; Palesh O; Kesler SR
Brain Imaging Behav; 2023 Jun; 17(3):320-328. PubMed ID: 37127832
[TBL] [Abstract][Full Text] [Related]
11. Potential moderators of physical activity on brain health.
Leckie RL; Weinstein AM; Hodzic JC; Erickson KI
J Aging Res; 2012; 2012():948981. PubMed ID: 23304508
[TBL] [Abstract][Full Text] [Related]
12. Genetic Risk Score Predicts Late-Life Cognitive Impairment.
Wollam ME; Weinstein AM; Saxton JA; Morrow L; Snitz B; Fowler NR; Suever Erickson BL; Roecklein KA; Erickson KI
J Aging Res; 2015; 2015():267062. PubMed ID: 26366299
[TBL] [Abstract][Full Text] [Related]
13. Fasting and Cognitive Impairment.
Tagliafico L; Nencioni A; Monacelli F
Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140367
[TBL] [Abstract][Full Text] [Related]
14. Editorial for "Altered Dynamics of Brain Spontaneous Activity and Functional Networks Associated with Cognitive Impairment in Patients with Type 2 Diabetes".
Khazaee A; Mohammadi A
J Magn Reson Imaging; 2024 Feb; ():. PubMed ID: 38411284
[No Abstract] [Full Text] [Related]
15. Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes.
Cowan BA; Olivier K; Tombal B; Wefel JS
Adv Ther; 2024 Apr; 41(4):1770-1773. PubMed ID: 38378976
[No Abstract] [Full Text] [Related]
16. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Estrada-Bernal A; Le AT; Doak AE; Tirunagaru VG; Silva S; Bull MR; Smaill JB; Patterson AV; Kim C; Liu SV; Doebele RC
Clin Cancer Res; 2021 Mar; 27(5):1463-1475. PubMed ID: 33355298
[TBL] [Abstract][Full Text] [Related]
17. Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial.
Berry DL; Hong F; Blonquist TM; Halpenny B; Xiong N; Filson CP; Master VA; Sanda MG; Chang P; Chien GW; Jones RA; Krupski TL; Wolpin S; Wilson L; Hayes JH; Trinh QD; Sokoloff M
Urol Oncol; 2021 Aug; 39(8):493.e9-493.e15. PubMed ID: 33353864
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy and cognitive decline-associations with brain connectomes, endocrine status, and risk genotypes.
Buskbjerg CR; Amidi A; Buus S; Gravholt CH; Hadi Hosseini SM; Zachariae R
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):208-218. PubMed ID: 34088994
[TBL] [Abstract][Full Text] [Related]
19. Cognitive changes and brain connectomes, endocrine status, and risk genotypes in testicular cancer patients-A prospective controlled study.
Buskbjerg CR; Amidi A; Agerbaek M; Gravholt CH; Hosseini SH; Zachariae R
Cancer Med; 2021 Sep; 10(18):6249-6260. PubMed ID: 34390226
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
